These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 10908844)
81. Chemotherapy for advanced urothelial tract tumors: the M-VAC regimen. Sternberg CN; Yagoda A; Scher HI Prog Clin Biol Res; 1988; 277():45-51. PubMed ID: 3054909 [No Abstract] [Full Text] [Related]
82. Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. Smith DC; Mackler NJ; Dunn RL; Hussain M; Wood D; Lee CT; Sanda M; Vaishampayan U; Petrylak DP; Quinn DI; Beekman K; Montie JE J Urol; 2008 Dec; 180(6):2384-8; discussion 2388. PubMed ID: 18930256 [TBL] [Abstract][Full Text] [Related]
83. Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). Bamias A; Dafni U; Karadimou A; Timotheadou E; Aravantinos G; Psyrri A; Xanthakis I; Tsiatas M; Koutoulidis V; Constantinidis C; Hatzimouratidis C; Samantas E; Visvikis A; Chrisophos M; Stravodimos K; Deliveliotis C; Eleftheraki A; Pectasides D; Fountzilas G; Dimopoulos MA Ann Oncol; 2013 Apr; 24(4):1011-7. PubMed ID: 23136231 [TBL] [Abstract][Full Text] [Related]
84. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. Dodd PM; McCaffrey JA; Hilton S; Mazumdar M; Herr H; Kelly WK; Icasiano E; Boyle MG; Bajorin DF J Clin Oncol; 2000 Feb; 18(4):840-6. PubMed ID: 10673526 [TBL] [Abstract][Full Text] [Related]
85. Second-line treatment of advanced transitional cell carcinoma of the urothelial tract. Sternberg CN Curr Opin Urol; 2001 Sep; 11(5):523-9. PubMed ID: 11493775 [TBL] [Abstract][Full Text] [Related]
90. Gemcitabine, paclitaxel, and cisplatin as combined adjuvant approach in transitional cell carcinoma of the urothelium. Ecke TD; Gerullis H; Bartel P; Koch S; Ruttloff J Minerva Urol Nefrol; 2009 Sep; 61(3):249-56. PubMed ID: 19773726 [TBL] [Abstract][Full Text] [Related]
91. Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience. Dorff TB; Tsao-Wei D; Miranda G; Skinner DG; Stein JP; Quinn DI World J Urol; 2009 Feb; 27(1):39-44. PubMed ID: 19020886 [TBL] [Abstract][Full Text] [Related]
92. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Edelman MJ; Clark JI; Chansky K; Albain K; Bhoopalam N; Weiss GR; Giguere JK; Kelly K; Crowley J; Gandara DR Clin Cancer Res; 2004 Aug; 10(15):5022-6. PubMed ID: 15297403 [TBL] [Abstract][Full Text] [Related]
93. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Siefker-Radtke AO; Dinney CP; Shen Y; Williams DL; Kamat AM; Grossman HB; Millikan RE Cancer; 2013 Feb; 119(3):540-7. PubMed ID: 22914978 [TBL] [Abstract][Full Text] [Related]
94. [The role of new drugs in the treatment of locally advanced urothelial tumors of the bladder]. Antoine EC; Khayat D Cancer Radiother; 1998 Apr; 2 Suppl 1():97s-102s. PubMed ID: 9749088 [TBL] [Abstract][Full Text] [Related]
95. [Role of gemcitabine/cisplatin in the treatment of advanced and metastatic bladder cancer]. Bodrogi I Magy Onkol; 2003; 47(2):198-203. PubMed ID: 12975670 [TBL] [Abstract][Full Text] [Related]
96. [Gemcitabine and carboplatin chemotherapy in advanced transitional cell carcinoma in regard to patients with impaired renal function]. Helke C; May M; Hoschke B Aktuelle Urol; 2006 Sep; 37(5):363-8. PubMed ID: 17004181 [TBL] [Abstract][Full Text] [Related]
97. Docetaxel in the management of advanced or metastatic urothelial tract cancer. Logothetis C; Millikan R Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):107-11. PubMed ID: 12108893 [TBL] [Abstract][Full Text] [Related]
98. Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy. Han KS; Joung JY; Kim TS; Jeong IG; Seo HK; Chung J; Lee KH Br J Cancer; 2008 Jan; 98(1):86-90. PubMed ID: 18087289 [TBL] [Abstract][Full Text] [Related]
99. Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma. Shelley MD; Cleves A; Wilt TJ; Mason MD BJU Int; 2011 Jul; 108(2):168-79. PubMed ID: 21718430 [TBL] [Abstract][Full Text] [Related]
100. Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAve. Gross-Goupil M; Domblides C; Lefort F; Ravaud A Bull Cancer; 2020 Jun; 107(5S):eS1-eS7. PubMed ID: 32620210 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]